Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
19
CYTOF Quote, Financials, Valuation and Earnings
Last price:
$0.08
Seasonality move
:
-11.79%
Day range:
$0.07 - $0.07
52-week range:
$0.05 - $0.58
Dividend yield:
0%
P/E ratio:
0.23x
P/S ratio:
--
P/B ratio:
0.08x
Volume:
21
Avg. volume:
7.2K
1-year change:
-86.68%
Market cap:
$303.3K
Revenue:
--
EPS (TTM):
-$1.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CYTOF
Altamira Therapeutics Ltd.
|
-- | -- | -- | -- | -- |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IGC
IGC Pharma, Inc.
|
$383K | -$0.02 | -7.04% | -11.5% | $3.75 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$17.9M | -- | -7.76% | -- | $11.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CYTOF
Altamira Therapeutics Ltd.
|
$0.07 | -- | $303.3K | 0.23x | $0.00 | 0% | -- |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
CVM
CEL-SCI Corp.
|
$6.45 | $42.50 | $19.6M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma, Inc.
|
$0.30 | $3.75 | $27.7M | -- | $0.00 | 0% | 22.36x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.21 | $0.85 | $152.5M | 2.03x | $0.80 | 0% | 2.35x |
|
PLX
Protalix Biotherapeutics, Inc.
|
$1.73 | $11.00 | $139.1M | 24.89x | $0.00 | 0% | 2.20x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CYTOF
Altamira Therapeutics Ltd.
|
-- | 3.714 | -- | -- |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.805 | 0.39% | 0.78x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -1.718 | 4.58% | 2.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CYTOF
Altamira Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
Altamira Therapeutics Ltd. vs. Competitors
-
Which has Higher Returns CYTOF or AIM?
AIM ImmunoTech has a net margin of -- compared to Altamira Therapeutics Ltd.'s net margin of -10571.43%. Altamira Therapeutics Ltd.'s return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital CYTOFAltamira Therapeutics Ltd.-- -- -- AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About CYTOF or AIM?
Altamira Therapeutics Ltd. has a consensus price target of --, signalling upside risk potential of 8066.96%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Altamira Therapeutics Ltd., analysts believe AIM ImmunoTech is more attractive than Altamira Therapeutics Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CYTOFAltamira Therapeutics Ltd.0 0 0 AIMAIM ImmunoTech1 0 0 -
Is CYTOF or AIM More Risky?
Altamira Therapeutics Ltd. has a beta of 2.800, which suggesting that the stock is 179.969% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock CYTOF or AIM?
Altamira Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altamira Therapeutics Ltd. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CYTOF or AIM?
Altamira Therapeutics Ltd. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Altamira Therapeutics Ltd.'s net income of -- is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Altamira Therapeutics Ltd.'s price-to-earnings ratio is 0.23x while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altamira Therapeutics Ltd. is -- versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CYTOFAltamira Therapeutics Ltd.-- 0.23x -- -- AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns CYTOF or CVM?
CEL-SCI Corp. has a net margin of -- compared to Altamira Therapeutics Ltd.'s net margin of --. Altamira Therapeutics Ltd.'s return on equity of -- beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital CYTOFAltamira Therapeutics Ltd.-- -- -- CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About CYTOF or CVM?
Altamira Therapeutics Ltd. has a consensus price target of --, signalling upside risk potential of 8066.96%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that Altamira Therapeutics Ltd. has higher upside potential than CEL-SCI Corp., analysts believe Altamira Therapeutics Ltd. is more attractive than CEL-SCI Corp..
Company Buy Ratings Hold Ratings Sell Ratings CYTOFAltamira Therapeutics Ltd.0 0 0 CVMCEL-SCI Corp.1 0 0 -
Is CYTOF or CVM More Risky?
Altamira Therapeutics Ltd. has a beta of 2.800, which suggesting that the stock is 179.969% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock CYTOF or CVM?
Altamira Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altamira Therapeutics Ltd. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CYTOF or CVM?
Altamira Therapeutics Ltd. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Altamira Therapeutics Ltd.'s net income of -- is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Altamira Therapeutics Ltd.'s price-to-earnings ratio is 0.23x while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altamira Therapeutics Ltd. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CYTOFAltamira Therapeutics Ltd.-- 0.23x -- -- CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns CYTOF or IGC?
IGC Pharma, Inc. has a net margin of -- compared to Altamira Therapeutics Ltd.'s net margin of -953.4%. Altamira Therapeutics Ltd.'s return on equity of -- beat IGC Pharma, Inc.'s return on equity of -94.42%.
Company Gross Margin Earnings Per Share Invested Capital CYTOFAltamira Therapeutics Ltd.-- -- -- IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M -
What do Analysts Say About CYTOF or IGC?
Altamira Therapeutics Ltd. has a consensus price target of --, signalling upside risk potential of 8066.96%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1158.81%. Given that Altamira Therapeutics Ltd. has higher upside potential than IGC Pharma, Inc., analysts believe Altamira Therapeutics Ltd. is more attractive than IGC Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CYTOFAltamira Therapeutics Ltd.0 0 0 IGCIGC Pharma, Inc.2 0 0 -
Is CYTOF or IGC More Risky?
Altamira Therapeutics Ltd. has a beta of 2.800, which suggesting that the stock is 179.969% more volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.
-
Which is a Better Dividend Stock CYTOF or IGC?
Altamira Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altamira Therapeutics Ltd. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CYTOF or IGC?
Altamira Therapeutics Ltd. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Altamira Therapeutics Ltd.'s net income of -- is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Altamira Therapeutics Ltd.'s price-to-earnings ratio is 0.23x while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altamira Therapeutics Ltd. is -- versus 22.36x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CYTOFAltamira Therapeutics Ltd.-- 0.23x -- -- IGCIGC Pharma, Inc.22.36x -- $191K -$1.8M
-
Which has Higher Returns CYTOF or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Altamira Therapeutics Ltd.'s net margin of -255.85%. Altamira Therapeutics Ltd.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital CYTOFAltamira Therapeutics Ltd.-- -- -- NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About CYTOF or NBY?
Altamira Therapeutics Ltd. has a consensus price target of --, signalling upside risk potential of 8066.96%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Altamira Therapeutics Ltd. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Altamira Therapeutics Ltd. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CYTOFAltamira Therapeutics Ltd.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is CYTOF or NBY More Risky?
Altamira Therapeutics Ltd. has a beta of 2.800, which suggesting that the stock is 179.969% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock CYTOF or NBY?
Altamira Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Altamira Therapeutics Ltd. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CYTOF or NBY?
Altamira Therapeutics Ltd. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Altamira Therapeutics Ltd.'s net income of -- is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Altamira Therapeutics Ltd.'s price-to-earnings ratio is 0.23x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altamira Therapeutics Ltd. is -- versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CYTOFAltamira Therapeutics Ltd.-- 0.23x -- -- NBYNovaBay Pharmaceuticals, Inc.2.35x 2.03x $521K -$1.3M
-
Which has Higher Returns CYTOF or PLX?
Protalix Biotherapeutics, Inc. has a net margin of -- compared to Altamira Therapeutics Ltd.'s net margin of 13.19%. Altamira Therapeutics Ltd.'s return on equity of -- beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital CYTOFAltamira Therapeutics Ltd.-- -- -- PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About CYTOF or PLX?
Altamira Therapeutics Ltd. has a consensus price target of --, signalling upside risk potential of 8066.96%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 535.84%. Given that Altamira Therapeutics Ltd. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe Altamira Therapeutics Ltd. is more attractive than Protalix Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CYTOFAltamira Therapeutics Ltd.0 0 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is CYTOF or PLX More Risky?
Altamira Therapeutics Ltd. has a beta of 2.800, which suggesting that the stock is 179.969% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.
-
Which is a Better Dividend Stock CYTOF or PLX?
Altamira Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altamira Therapeutics Ltd. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CYTOF or PLX?
Altamira Therapeutics Ltd. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Altamira Therapeutics Ltd.'s net income of -- is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Altamira Therapeutics Ltd.'s price-to-earnings ratio is 0.23x while Protalix Biotherapeutics, Inc.'s PE ratio is 24.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altamira Therapeutics Ltd. is -- versus 2.20x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CYTOFAltamira Therapeutics Ltd.-- 0.23x -- -- PLXProtalix Biotherapeutics, Inc.2.20x 24.89x $17.9M $2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 65.44% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 8.33% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.85% over the past day.
